Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30 September2024.
Highlights from this period include:
- Specification testing of drug product from GMP production run of PAT-DX1 completed;
- Based on results of specification testing, Patrys to focus internal development efforts on PAT-DX3 and seek partnering or licensing opportunities for PAT-DX1;
- Cash and short‑term investment balance of $1.3 million on 30 September 2024, with an R&D refund of $1.3 million expected in the current quarter